I joined Genentech in 2006 in the Oncology Department’s in vivo pharmacology group. Prior to Genentech, I was a Principle Scientist at Wyeth Research in the Department of Oncology focusing on the discovery and preclinical pharmacology of novel anti-microtubule agents. Since joining Genentech I have worked on small molecule drug discovery programs focusing on two areas of interest that include targeting the PI3K pathway and Bcl-2 family of pro-survival proteins. The best part of my job as a pharmacologist at Genentech is the opportunity to work with a number of highly motivated, passionate and extremely talented preclinical and clinical scientists all of whom share a common goal to discover and develop medicines that will help patients.
Mol Cancer Ther. 2016 May;15(5):1132-44.
My lab focuses on evaluating the efficacy, pharmacokinetics, pharmacodynamics and mechanism of action of small molecules and biologics against select targets that play a fundamental role in tumor growth and survival in vivo. We utilize or generate cancer models derived from human and murine cell lines as well those established directly from patient tumors (commonly referred to as patient-derived xenografts). In addition, the lab focuses on determining the relationship between pharmacokinetics, pharmacodynamics and efficacy of lead drug candidates and new molecular entities as single agents or in combination with standard of care therapies to support clinical development and define predictive biomarkers of response. For the past 11 years, we have focused our efforts primarily on small molecule drug discovery programs that target the PI3K pathway and BCL-2 family of apoptotic proteins for development in solid tumors, such as breast cancer, and hematological malignancies. The group also supports the evaluation of novel biologics (antibody-drug conjugates) directed against certain cancer targets. I have also dedicated my efforts towards leading small molecule project teams from early stage research to clinical development.